Used in targeted cancer therapy, particularly for tumors overexpressing FGFR3, such as certain bladder, cervical, and multiple myeloma cancers. Acts by binding specifically to FGFR3 on cancer cells, marking them for immune destruction or delivering conjugated drugs directly to tumor cells. Enables precise targeting, reducing damage to healthy tissues. Investigated in clinical trials for efficacy in combination with other immunotherapies or chemotherapeutic agents. Shows potential in overcoming resistance to conventional treatments by inhibiting FGFR3-mediated signaling pathways involved in tumor growth and survival.